Pictet Asset Management Holding SA Has $13.19 Million Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Pictet Asset Management Holding SA increased its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 9.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 598,487 shares of the company's stock after acquiring an additional 52,938 shares during the period. Pictet Asset Management Holding SA owned about 0.05% of Teva Pharmaceutical Industries worth $13,191,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Clal Insurance Enterprises Holdings Ltd grew its position in Teva Pharmaceutical Industries by 12.8% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock valued at $859,935,000 after purchasing an additional 4,418,961 shares in the last quarter. Lingotto Investment Management LLP boosted its stake in shares of Teva Pharmaceutical Industries by 2.6% during the 4th quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company's stock worth $599,320,000 after buying an additional 688,862 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its holdings in shares of Teva Pharmaceutical Industries by 2.2% in the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company's stock valued at $573,822,000 after acquiring an additional 569,412 shares in the last quarter. State Street Corp increased its position in shares of Teva Pharmaceutical Industries by 10.0% in the third quarter. State Street Corp now owns 19,500,683 shares of the company's stock valued at $351,402,000 after acquiring an additional 1,778,268 shares during the last quarter. Finally, AustralianSuper Pty Ltd raised its holdings in Teva Pharmaceutical Industries by 16.8% during the fourth quarter. AustralianSuper Pty Ltd now owns 9,222,695 shares of the company's stock worth $203,268,000 after acquiring an additional 1,329,319 shares in the last quarter. 54.05% of the stock is owned by institutional investors.

Remove Ads

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA traded down $0.45 during trading on Thursday, reaching $14.85. 8,174,233 shares of the stock were exchanged, compared to its average volume of 9,702,144. The firm has a market cap of $16.83 billion, a PE ratio of -10.24, a PEG ratio of 1.44 and a beta of 0.82. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a 12 month low of $12.51 and a 12 month high of $22.80. The stock has a 50-day moving average price of $16.81 and a 200-day moving average price of $18.06.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Research analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. StockNews.com lowered Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research report on Thursday, March 27th. Bank of America cut their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. Piper Sandler boosted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. UBS Group cut their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research note on Thursday, January 30th. Finally, Barclays dropped their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, January 30th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.